RegCell
6 known investors
RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
Founders & leadership
MM
Michael McCullar, PhDChief Executive Officer
JA
James AhlersChief Financial Officer
MG
Marty Giedlin, PhDChief Technology Officer
TH
Tony HurleyChief Technical Operations Officer
SK
Steve Kanner, PhDChief Scientific Officer
Investors · 6
Fast Track InitiativeTokyo · $1.2M – $184M
Global BrainTokyo · $100K – $184M
Kyoto University Innovation CapitalKyoto
UTECTokyo · $3.1M – $78M
Mitsubishi UFJ CapitalreportedTokyo · $952K – $269M
Also in the syndicate · 1
Celadon Partners
Funding
SEC filings, press & company announcements$45M disclosed across 1 of 2 rounds · 2025
- Undisclosed amountseed roundMar 2025
Fast Track Initiative (FTI) (lead), The University of Tokyo Edge Capital Partners (UTEC) (lead), Celadon Partners, Kyoto University Innovation Capital (Kyoto i-Cap), Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC)
Source ↗ - $45MraisedMar 2025 · 4 sources
Fast Track Initiative (FTI) (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 3
by search overlapRegeneron NASDAQ: REGN www.regeneron.com5 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Read on Scientific American4 shared keywordsScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.
Lyell4 shared keywordsLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
Companies competing with RegCell for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does RegCell do?
- RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.
- Who are RegCell's investors?
- RegCell's investors include Fast Track Initiative, Global Brain, Kyoto University Innovation Capital, UTEC, Mitsubishi UFJ Capital.
- How much funding has RegCell raised?
- RegCell has disclosed $45M raised across 1 of its 2 known rounds.